Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2013; 138(20): 1073-1076
DOI: 10.1055/s-0033-1343111
DOI: 10.1055/s-0033-1343111
Kommentar | Commentary
Pathologie, Onkologie
Klinische Studien in der Onkologie: eine Herausforderung für die klinische und akademische Pathologie
Clinical studies in oncology – a challenge for clinical and academic pathologyFurther Information
Publication History
18 February 2013
12 April 2013
Publication Date:
13 May 2013 (online)
-
Literatur
- 1 Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA). Lancet 2010; 376: 687-697
- 2 Bossuyt PM, Reitsma JB, Bruns DE et al. Toward complete and accurate reporting of studies of diagnostic accuracy. The STARD initiative. Am J Clin Pathol 2003; 119: 18-22
- 3 Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes – a systematic review. Int J Cancer 2012; 130: 2845-2856
- 4 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674
- 5 Herpel E, Röcken C, Manke H et al. Quality management and accreditation of research tissue banks: experience of the National Center for Tumor Diseases (NCT) Heidelberg. Virchows Arch 2010; 457: 741-747
- 6 Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805
- 7 Jörgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer. J Cancer 2012; 3: 137-144
- 8 Lordick F, Röcken C. The identification of predictive factors for perioperative chemotherapy in esophago-gastric cancer. Ann Oncol 2013; Mar 19. [Epub ahead of print]
- 9 Manke H, Röcken C. Accreditation in pathology. Pathologe 2008; 29: 388-402
- 10 McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-9072
- 11 Rüschoff J, Dietel M, Baretton G et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457: 299-307
- 12 Verband Forschender Arzneimittelhersteller (VFA). Entwicklungsprojekte für innovative Arzneimittel Bessere Medikamente in Sicht: Perspektive 2015. http://www.vfa.de/de/arzneimittel-forschung/woran-wir-forschen/bessere-medikamente-in-sicht-perspektive-2015.html/_1/_2/_3/_4 (letzter Zugriff 11.4.2013)
- 13 Verband Forschender Arzneimittelhersteller (VFA). In Deutschland zugelassene Arzneimittel für die personalisierte Medizin. http://www.vfa.de/de/arzneimittel-forschung/datenbanken-zu-arzneimitteln/individualisierte-medizin.html (letzter Zugriff 11.4.2013)